BRAVACCINI, SARA
 Distribuzione geografica
Continente #
NA - Nord America 189
EU - Europa 158
AS - Asia 88
AF - Africa 34
Totale 469
Nazione #
US - Stati Uniti d'America 189
SG - Singapore 55
IT - Italia 51
GB - Regno Unito 28
CI - Costa d'Avorio 24
DE - Germania 21
SE - Svezia 20
VN - Vietnam 12
CN - Cina 10
IE - Irlanda 9
IN - India 8
TG - Togo 7
BG - Bulgaria 5
FR - Francia 5
FI - Finlandia 4
CZ - Repubblica Ceca 3
RU - Federazione Russa 3
CH - Svizzera 2
EE - Estonia 2
ZA - Sudafrica 2
HK - Hong Kong 1
LU - Lussemburgo 1
NG - Nigeria 1
NO - Norvegia 1
PL - Polonia 1
PT - Portogallo 1
TH - Thailandia 1
TR - Turchia 1
UA - Ucraina 1
Totale 469
Città #
Singapore 51
Southend 28
Abidjan 24
Chandler 20
Fairfield 16
Ashburn 15
Santa Clara 12
Dublin 9
Princeton 8
Woodbridge 8
Houston 7
Lomé 7
Bologna 5
New York 5
Rome 5
Seattle 5
Sofia 5
Wilmington 5
Milan 4
Berlin 3
Bremen 3
Brno 3
Cambridge 3
Frankfurt am Main 3
Imola 3
Turin 3
Westminster 3
Beijing 2
Bern 2
Carpi 2
Catanzaro 2
Frattamaggiore 2
Helsinki 2
Lappeenranta 2
Monzuno 2
Naples 2
Redwood City 2
Saint Petersburg 2
Senago 2
Abeokuta 1
Ann Arbor 1
Bagnacavallo 1
Bangkok 1
Boston 1
Boydton 1
Bühl 1
Central 1
Changchun 1
Cirò Marina 1
Colleferro 1
Des Moines 1
Florence 1
Guangzhou 1
Hyderabad 1
Istanbul 1
Jiaxing 1
Jinan 1
Lisbon 1
Luxembourg 1
Medford 1
Miami 1
Mülheim 1
Nanjing 1
Padova 1
Parma 1
Pizzo 1
Pune 1
San Diego 1
Savignano sul Rubicone 1
Shanghai 1
Verona 1
Warsaw 1
Washington 1
Totale 321
Nome #
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data 96
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients 81
Cancer region detection by visual features in histopathology 76
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 67
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 28
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ 18
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 17
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 17
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 16
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 15
Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension 14
Why the complications of COVID-19 patients differ in elderly and young cancer patients 11
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon 9
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 9
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 9
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter 7
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 7
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 7
Sorafenib for the treatment of breast cancer 6
Are we ready to use TMB in breast cancer clinical practice? 3
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 3
Palbociclib (PD 0332991): Targeting the cell cycle machinery in breast cancer 3
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy 3
Totale 522
Categoria #
all - tutte 2.255
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.255


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202037 0 2 0 0 4 2 4 7 5 7 3 3
2020/202148 9 2 2 0 1 2 0 11 4 0 2 15
2021/202258 2 1 2 2 5 2 1 4 4 4 18 13
2022/2023113 8 17 6 11 5 16 1 5 22 0 8 14
2023/2024112 6 10 14 7 1 12 4 4 33 8 8 5
2024/2025126 42 84 0 0 0 0 0 0 0 0 0 0
Totale 522